二甲双胍治疗超重或肥胖患者膝骨关节炎:一项随机临床试验
这项社区随机双盲安慰剂对照试验在澳大利亚维多利亚州通过远程医疗招募107例有症状膝骨关节炎且超重或肥胖的参与者,随机接受口服二甲双胍2000 mg/d或安慰剂治疗6个月。6个月时二甲双胍组VAS疼痛平均变化-31.3 mm,安慰剂组-18.9 mm,组间差异-11.4 mm(95%CI -20.1至-2.6 mm;P=0.01)。作者认为结果支持二甲双胍用于治疗超重或肥胖者的有症状膝骨关节炎,但因样本量不大需在更大临床试验中确认。
要点
- 6个月时二甲双胍组VAS疼痛平均降低31.3 mm,安慰剂组降低18.9 mm,组间差异-11.4 mm(95%CI -20.1至-2.6 mm;P=0.01)。
- 效应量(标准化均数差)为0.43(95%CI 0.02-0.83)。
- 最常见不良事件为腹泻(二甲双胍组8例[15%] vs 安慰剂组4例[8%])和腹部不适(7例[13%] vs 5例[9%])。
核心结论
- 作者认为这些结果支持二甲双胍用于治疗超重或肥胖者的有症状膝骨关节炎。
- 作者指出因样本量不大,需在更大临床试验中确认。
研究设计与样本
- 社区-based随机、平行组、双盲、安慰剂对照临床试验,使用远程医疗招募和远程随访参与者。
- 2021年6月16日至2023年8月1日期间通过当地和社交媒体广告在澳大利亚维多利亚州社区招募,末次随访于2024年2月8日。
- 纳入标准为膝关节疼痛6个月或以上、100 mm视觉模拟量表(VAS)疼痛评分大于40 mm、体重指数25或以上。
- 225例参与者接受资格评估,107例(48%)被随机分组(平均年龄58.8岁[SD 9.5];68%女性),二甲双胍组54例、安慰剂组53例。
- 88例参与者(82%)完成试验。
主要发现
- 干预为口服二甲双胍2000 mg/d(n=54)或相同安慰剂(n=53),疗程6个月。
- 主要结局为6个月时100 mm VAS(评分范围0-100;100=最差;最小临床重要差异=15)测量的膝关节疼痛变化。
- 6个月时VAS疼痛平均变化二甲双胍组为-31.3 mm,安慰剂组为-18.9 mm(组间差异-11.4 mm;95%CI -20.1至-2.6 mm;P=0.01)。
- 效应量(标准化均数差)为0.43(95%CI 0.02-0.83)。
- 最常见不良事件为腹泻(二甲双胍组8例[15%] vs 安慰剂组4例[8%])和腹部不适(二甲双胍组7例[13%] vs 安慰剂组5例[9%])。
临床怎么用
- 作者认为结果支持二甲双胍用于治疗超重或肥胖者的有症状膝骨关节炎。
- 作者指出因样本量不大,需在更大临床试验中确认。
局限性
- 作者指出因样本量不大,需在更大临床试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Preclinical and preliminary human evidence suggests that metformin, a first-line treatment for type 2 diabetes, reduces inflammation, preserves cartilage, and improves knee pain in knee osteoarthritis. OBJECTIVE: To evaluate the effects of metformin on knee pain at 6 months in participants with symptomatic knee osteoarthritis and overweight or obesity. DESIGN, SETTING, AND PARTICIPANTS: Community-based randomized, parallel-group, double-blind, placebo-controlled clinical trial that used telemedicine to recruit and follow up participants remotely. Individuals with knee pain for 6 months or longer, a pain score greater than 40 mm on a 100-mm visual analog scale (VAS), and body mass index of 25 or higher were recruited from the community through local and social media advertisements in Victoria, Australia, between June 16, 2021, and August 1, 2023. Final follow-up occurred on February 8, 2024. INTERVENTIONS: Participants were randomly assigned to receive either oral metformin, 2000 mg/d (n = 54), or identical placebo (n = 53) for 6 months. MAIN OUTCOMES AND MEASURES: The primary outcome was change in knee pain, measured using a 100-mm VAS (score range, 0-100; 100 = worst; minimum clinically important difference = 15) at 6 months. RESULTS: Of 225 participants assessed for eligibility, 107 (48%) were randomized (mean age, 58.8 [SD, 9.5] years; 68% female) and assigned to receive metformin or placebo. Eighty-eight participants (82%) completed the trial. At 6 months, the mean change in VAS pain was -31.3 mm in the metformin group and -18.9 mm in the placebo group (between-group difference, -11.4 mm; 95% CI, -20.1 to -2.6 mm; P = .01), corresponding to an effect size (standardized mean difference) of 0.43 (95% CI, 0.02-0.83). The most common adverse events were diarrhea (8 [15%] in the metformin group and 4 [8%] in the placebo group) and abdominal discomfort (7 [13%] in the metformin group and 5 [9%] in the placebo group). CONCLUSIONS AND RELEVANCE: These results support use of metformin for treatment of symptomatic knee osteoarthritis in people with overweight or obesity. Because of the modest sample size, confirmation in a larger clinical trial is warranted. TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12621000710820.
引用
- Pan F, Wang Y, Lim YZ, et al. Metformin for Knee Osteoarthritis in Patients With Overweight or Obesity: A Randomized Clinical Trial. JAMA. 2025. PMID: 40274279. doi:10.1001/jama.2025.3471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。